SYNGENE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.5
| Stock Code | SYNGENE | Market Cap | 19,224 Cr. | Current Price | 477 ₹ | High / Low | 729 ₹ |
| Stock P/E | 53.2 | Book Value | 117 ₹ | Dividend Yield | 0.26 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 441 ₹ | DMA 200 | 551 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 67.7 | MACD | 10.4 | Volume | 48,40,854 | Avg Vol 1Wk | 1,76,25,337 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -6.32 | Debt to equity | 0.04 |
| 52w Index | 27.9 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 41.1 |
📊 Analysis: Syngene International (SYNGENE) has a market cap of ₹19,224 Cr and trades at a high P/E of 53.2 compared to the industry average of 41.1, indicating premium valuation. ROE (7.74%) and ROCE (10.0%) are modest, reflecting average efficiency. EPS of ₹7.57 is relatively low, and dividend yield of 0.26% offers minimal income support. The PEG ratio of -6.32 highlights poor growth alignment. PAT rose sequentially (₹154 Cr vs ₹68.7 Cr), but quarterly profit variation (-11.8%) shows volatility. Current price (₹477) is above DMA 50 (₹441) but below DMA 200 (₹551), suggesting short-term momentum but long-term weakness.
💰 Entry Price Zone: Ideal accumulation range is ₹430–460, closer to the 50 DMA (₹441). This zone offers better risk-reward compared to current levels.
📈 Exit / Holding Strategy: If already holding, maintain a medium-term horizon (2–3 years) but monitor earnings growth closely. Consider partial profit booking near ₹550–600 resistance levels. Long-term holding is less attractive unless ROE and PAT growth improve significantly.
✅ Positive
- Strong sequential PAT growth (₹154 Cr vs ₹68.7 Cr)
- Low debt-to-equity ratio (0.04)
- DII holdings increased (+0.61%)
- Stock trading above 50 DMA shows short-term strength
⚠️ Limitation
- High P/E (53.2) vs industry average (41.1)
- Weak ROE (7.74%) and ROCE (10.0%)
- PEG ratio (-6.32) signals poor growth valuation
- Dividend yield (0.26%) is negligible
📉 Company Negative News
- Quarterly profit variation (-11.8%) shows volatility
- FII holdings declined (-1.05%)
📈 Company Positive News
- PAT improved sequentially from ₹68.7 Cr to ₹154 Cr
- DII holdings increased (+0.61%) showing domestic investor confidence
🏦 Industry
- Biotech & pharma services sector trades at P/E of 41.1, lower than Syngene’s valuation
- Industry growth supported by global demand for contract research and drug development
🔎 Conclusion
Syngene is a moderate candidate for long-term investment, supported by low debt and sequential profit improvement but weighed down by high valuation, weak ROE/ROCE, and poor PEG ratio. Entry around ₹430–460 is preferable. Existing holders should consider a 2–3 year horizon, booking profits near ₹550–600 resistance levels while monitoring earnings growth closely.